Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
RPTX 
Repare Therapeutics Inc (RPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: RPTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.86% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 110.79M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 4 | Beta 1.02 | 52 Weeks Range 0.89 - 2.66 | Updated Date 12/28/2025 |
52 Weeks Range 0.89 - 2.66 | Updated Date 12/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3.7% |
Management Effectiveness
Return on Assets (TTM) -29.72% | Return on Equity (TTM) -49.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1473510 | Price to Sales(TTM) 9.33 |
Enterprise Value -1473510 | Price to Sales(TTM) 9.33 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 0.58 | Shares Outstanding 43108362 | Shares Floating 25786295 |
Shares Outstanding 43108362 | Shares Floating 25786295 | ||
Percent Insiders 1.21 | Percent Institutions 57.46 |
Upturn AI SWOT
Repare Therapeutics Inc
Company Overview
History and Background
Repare Therapeutics Inc. was founded in 2017, emerging from a collaboration between the Universitu00e9 de Montru00e9al and the Broad Institute of MIT and Harvard. The company is focused on developing novel precision oncology therapeutics. A significant milestone was its initial public offering (IPO) on the Nasdaq in July 2020, raising $155 million. Repare Therapeutics has since focused on advancing its pipeline of targeted cancer therapies.
Core Business Areas
- Precision Oncology Therapeutics: Repare Therapeutics is dedicated to discovering, developing, and commercializing a new class of precision oncology therapeutics. Their approach centers on understanding and targeting DNA damage response (DDR) pathways, aiming to create synthetic lethality in cancer cells.
- Drug Discovery and Development Platform: The company leverages its proprietary platform, which integrates genomics, bioinformatics, and drug discovery technologies, to identify novel drug targets and develop first-in-class therapeutics.
Leadership and Structure
Repare Therapeutics is led by a management team with extensive experience in biotechnology and pharmaceutical drug development. The exact organizational structure is typical of a publicly traded biotech company, with distinct departments for research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- RP-6306 (Mini-PARP Inhibitor): RP-6306 is a first-in-class mini-PARP inhibitor designed to target cancers with synthetic lethality. It is currently in clinical development, including a Phase 1 study for patients with solid tumors and certain lymphomas. Competitors in the broader PARP inhibitor space include companies like AstraZeneca (Lynparza) and Pfizer (Xalkori), though RP-6306's 'mini-PARP' mechanism is distinct. Market share data for RP-6306 is not yet available as it is in early-stage development.
- RP-3455 (ATR Inhibitor): RP-3455 is an investigational ATR inhibitor. ATR (ataxia telangiectasia and Rad3-related) is a key protein involved in DNA damage response. RP-3455 is being explored in combination with other therapies for various solid tumors. Competitors in the ATR inhibitor space include companies like Vertex Pharmaceuticals and Novartis. Market share data for RP-3455 is not yet available as it is in early-stage development.
- Other Pipeline Assets: Repare Therapeutics has a pipeline of other promising drug candidates targeting various DDR pathways, including SLFN11 activators and other novel targets. These are at various stages of preclinical and early clinical development.
Market Dynamics
Industry Overview
The precision oncology market is a rapidly growing segment of the pharmaceutical industry, driven by advancements in genomic sequencing, a deeper understanding of cancer biology, and the development of targeted therapies. The focus is on identifying specific genetic alterations in tumors to guide treatment decisions, leading to more effective and less toxic therapies.
Positioning
Repare Therapeutics is positioned as an innovator in the field of DNA damage response (DDR) targeted therapies. Their unique platform and focus on synthetic lethality offer a potential competitive advantage by addressing a broad range of cancers with specific genetic vulnerabilities. Their strategic partnerships and strong scientific foundation contribute to their positioning.
Total Addressable Market (TAM)
The TAM for precision oncology therapeutics is substantial and rapidly expanding. It is estimated to be in the tens of billions of dollars globally and is projected to continue growing significantly with the advancement of new targeted therapies. Repare Therapeutics is positioning itself to capture a share of this market by developing first-in-class therapies for various cancer types that rely on DDR pathways.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform focused on DDR pathways.
- Strong scientific foundation and experienced leadership team.
- First-in-class pipeline candidates with potential for significant therapeutic impact.
- Strategic partnerships with leading research institutions.
- Successful IPO provides capital for further development.
Weaknesses
- Early-stage development of all pipeline assets means significant clinical and regulatory hurdles remain.
- High reliance on the success of a few key drug candidates.
- Limited historical financial performance due to being a relatively young company.
- Biotech industry is inherently high-risk with high failure rates.
Opportunities
- Growing understanding of DDR pathways and synthetic lethality in cancer.
- Potential for broad application of DDR inhibitors across various cancer types.
- Strategic collaborations and licensing opportunities with larger pharmaceutical companies.
- Expansion into new therapeutic areas or indications based on platform insights.
- Advancements in companion diagnostics to identify patient populations.
Threats
- Clinical trial failures leading to pipeline setbacks.
- Competition from other companies developing similar DDR inhibitors or novel cancer therapies.
- Regulatory hurdles and lengthy approval processes.
- Changes in healthcare reimbursement policies.
- Patent challenges and intellectual property disputes.
Competitors and Market Share
Key Competitors
- Inovio Pharmaceuticals, Inc. (INO)
- Seagen Inc. (SGEN) (now part of Pfizer)
- BeiGene, Ltd. (BGNE)
- Arcus Biosciences, Inc. (RCUS)
- Gritstone Oncology, Inc. (GRTS)
Competitive Landscape
Repare Therapeutics faces intense competition from established pharmaceutical companies and numerous emerging biotechnology firms in the oncology space. Its competitive advantages lie in its specialized focus on DDR pathways and synthetic lethality, which could lead to novel therapeutic approaches. However, it faces challenges in terms of the extensive resources of larger competitors and the high risk associated with drug development.
Growth Trajectory and Initiatives
Historical Growth: Repare Therapeutics has experienced growth in terms of its pipeline advancement, team expansion, and market capitalization since its inception and IPO. The company has successfully moved its lead candidates into clinical trials.
Future Projections: Future growth projections are highly dependent on the success of its ongoing clinical trials and the eventual commercialization of its drug candidates. Analyst expectations would focus on milestones such as successful Phase 2/3 trial results, regulatory submissions, and potential market entry dates. These are speculative and subject to significant risk.
Recent Initiatives: Recent initiatives likely include the ongoing clinical trials for RP-6306 and RP-3455, potential new drug candidate discoveries, and strategic collaborations or partnerships to advance its pipeline.
Summary
Repare Therapeutics Inc. is a promising clinical-stage biotechnology company focused on innovative DDR-targeted cancer therapies. Its strengths lie in its proprietary platform and early-stage pipeline, but it faces significant risks inherent in drug development. Key opportunities exist in the growing precision oncology market and strategic partnerships. The company needs to carefully navigate clinical and regulatory pathways and manage its cash burn effectively.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company's official SEC filings (10-K, 10-Q, S-1)
- Repare Therapeutics Inc. Investor Relations website
- Financial data aggregators (e.g., Yahoo Finance, MarketWatch, Bloomberg)
- Industry reports on precision oncology
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Stock market investments are subject to inherent risks, and investors should conduct their own due diligence or consult with a qualified financial advisor before making any investment decisions. Market share data is estimated and may not be precise. Financial data is subject to change and reporting nuances of pre-revenue biotech companies.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repare Therapeutics Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2020-06-19 | President, CFO, CEO & Director Mr. Steve Forte CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 129 | Website https://www.reparerx.com |
Full time employees 129 | Website https://www.reparerx.com | ||
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.